Amneal Pharmaceuticals Inc. (AMRX) kicked off the year with a bang, generating record levels of revenue in the first quarter. With its business segments firing on all cylinders, the company is poised for 6.7% to 10.8% revenue growth in 2024.
This global pharmaceutical company develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals. It has three reportable segments - Generics, Specialty, and AvKARE.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.